الفهرس Only 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
Postmenopausal estrogen deficiency may result in a wide
variety of anatomic and physiologic disorders including vaso-
motor symptoms such as ”hot flushes, weakness, faintness,
insomnia, and palpitation” Urogenital symptoms such as
”vaginal dryness or burning, dyspareunia, urinary incontinence,
urithritis, and recurrent urinary tract infection”, psycho-logical
disturbances such as mood changes (depression, anxiety,
irritability, fatigue, insomnia, forgetfulness, decreased self-
esteem or decreased libido). Osteoprotic changes and fractures.,
An increase in the risk of coronary heart disease
The growing body of evidence including much that is
newly published demonstrating that hormone replacement
therapy (HR T) can largely prevent or mitigate these
complications with menopause.
The efficacy of hormone replacement therapy in
alleviating vasomotor and urogenital discomfort the most
common symptoms of postmenopausal estrogen deficiency, is
will established.
Evidence from over 30 epidemiological studies indicates
that estrogen reduces the risk of coronary heart disease (CHO)
by 50%. The risk of major coronary heart disease (CHD) has
been found to be markedly reduced in women who receive
combined estrogen/Progesterone therapy compared to non-users
(or estrogen alone users).